11/20/2025
We are thrilled to share key insights from our recent Forum in New York City, highlighted in a compelling article by Life Science Leader, in which Marty Makary, M.D., M.P.H. reflected on the future of pharmaceutical innovation.
- Accelerating reviews: Commissioner Makary emphasized the urgent need to “cut the idle time” within the U.S. Food and Drug Administration so that transformative therapies reach patients faster.
- Embracing “continuous trials”: In an era of unprecedented global competition—particularly from China—he proposed a paradigm shift toward more continuous and seamless trial models leveraging cloud-endpoints and real-time regulatory visibility.
- Modernizing pre-clinical review: The conversation also touched on the potential to replace or reduce animal testing through advanced technologies like organ-on-a-chip and computational modelling.
We thank Life Science Leader for shining a spotlight on these conversations, and all our stakeholders—industry partners, regulators, academia and patient advocates—for sharing this bold vision for the future.
Read more:
Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.
